Stockscreener 앱 받기
5.8714
1.23%
0.0714
전일 마감가:
$5.80
열려 있는:
$5.85
하루 거래량:
5,752
Relative Volume:
0.16
시가총액:
$21.32M
수익:
-
순이익/손실:
$-14.56M
주가수익비율:
-0.3491
EPS:
-16.82
순현금흐름:
$-12.46M
1주 성능:
+14.23%
1개월 성능:
-9.53%
6개월 성능:
+20.56%
1년 성능:
+68.72%
1일 변동 폭
$5.6396
$5.9976
1주일 범위
$4.63
$5.9976
52주 변동 폭
$2.77
$7.89
Tenax Therapeutics Inc Stock (TENX) Company Profile
명칭
Tenax Therapeutics Inc
전화
919-855-2100
주소
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
TENX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
5.8714 | 21.32M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | Leerink Partners | Outperform |
| 2024-10-14 | 개시 | Guggenheim | Buy |
| 2024-09-30 | 개시 | William Blair | Outperform |
| 2017-05-18 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 개시 | MLV & Co | Buy |
| 2014-11-18 | 개시 | WallachBeth | Buy |
모두보기
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
Form SC 13G/AStatement of Beneficial Ownership by Certain Investors: [Amend] - ADVFN
SEC Form DEF 14A filed by Tenax Therapeutics Inc. - Quantisnow
Form DEF 14A TENAX THERAPEUTICS, INC. For: Apr 24 - StreetInsider
Tenax Therapeutics Advances Cardiopulmonary Therapies - TipRanks
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - The Globe and Mail
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com - Defense World
Oxygen Biotherapeutics, Inc. : Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast - marketscreener.com
Teanx Therapeutics plans secondary offering - MSN
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha
Tenax Therapeutics (TENX) Files Prospectus for Stock Resale - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com - Defense World
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan
What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World
Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World
Q1 Earnings Estimate for TENX Issued By William Blair - Defense World
Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Research Analysts Set Expectations for TENX Q1 Earnings - Defense World
When (TENX) Moves Investors should Listen - news.stocktradersdaily.com
Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bluefield Daily Telegraph
Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost - Stock Titan
Tenax Therapeutics Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com - Defense World
Tenax Therapeutics (TENX) to Release Earnings on Thursday - Defense World
Plastic Fencing Market to be Driven by Growing Residential and Commercial Construction Activities, Exclusive Research by The Insight Partners - GlobeNewswire Inc.
Tenax Therapeutics (NASDAQ:TENX) Given “Outperform” Rating at William Blair - Defense World
Promising Developments and Financial Backing Drive Buy Rating for Tenax Therapeutics - TipRanks
What is Roth Capital’s Estimate for TENX FY2024 Earnings? - Defense World
Roth Capital Predicts Weaker Earnings for Tenax Therapeutics - Defense World
(TENX) Proactive Strategies - news.stocktradersdaily.com
Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewswire
Tenax Therapeutics announces $25M private placement - MSN
Tenax Therapeutics prices 378,346 shares at $6.04 in private placement - TipRanks
Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103 - TipRanks
Tenax Therapeutics secures $25 million in private placement - Investing.com India
Tenax Therapeutics Announces $25 Million Private Placement -March 05, 2025 at 08:54 am EST - Marketscreener.com
Tenax Therapeutics secures $25 million in private placement By Investing.com - Investing.com UK
Tenax Therapeutics Secures $25 Million From RTW Investments For Phase 3 Clinical Trials - StockTitan
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - Yahoo Finance
Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffs - Endpoints News
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
Can Tenax Therapeutics' Conference Appearance Signal New Cardiovascular Treatment Progress? - StockTitan
Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017 - ACCESS Newswire
Tenax Therapeutics Inc (TENX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
자본화:
|
볼륨(24시간):